Leukine (sargramostim) — CareFirst (Caremark)
Myelodysplastic syndrome (anemia or neutropenia)
Initial criteria
- Authorization may be granted for members with any of the listed indications.
Reauthorization criteria
- Member must continue to meet all requirements in the coverage criteria.
Approval duration
6 months